

(log rank,  $p=0.003$ ). Grade 3 histology or lymph node involvement at the time of salvage therapy did not predict for poorer outcomes. There were no acute or late grade 3 or higher toxicities observed in this cohort.

**Conclusion:** Salvage therapy with modern external beam radiation and image-guided brachytherapy is associated with excellent locoregional control and limited treatment-related side effects, comparing favorably with historical outcomes. In our cohort, patients with later relapses, with a median time to recurrence greater than 14.5 months, had improved outcomes with significantly greater distant metastases free survival at 2 years. Longer follow-up and prospective studies are needed to better characterize the efficacy and toxicity of this therapy.

**Author Disclosure:** A. Burr: None. D.M. Francis: None. A. Kuczmarska-Haas: None. N.R. Rydzewski: None. B.M. Anderson: Partner; University of Wisconsin. K.A. Bradley: Honoraria; UpToDate.

## 2805

### Validation of the ESMO-ESGO-ESTRO Consensus Conference Risk Grouping in Turkish Endometrial Cancer Patients Treated with Comprehensive Surgical Staging



M. Gultekin,<sup>1</sup> O.C. Guler,<sup>2</sup> S. Yuce Sari,<sup>3</sup> B. Akkus Yildirim,<sup>2</sup> T.Z. Mustafayev,<sup>4</sup> B. Atalar,<sup>5</sup> Y. Bolukbasi,<sup>6</sup> H.C. Onal,<sup>7</sup> H. Celik,<sup>7</sup> K. Yuce,<sup>8</sup> A. Ayhan,<sup>9</sup> and F. Yildiz<sup>10</sup>; <sup>1</sup>Hacettepe University Faculty of Medicine, Department of Radiation Oncology, Ankara, Turkey, <sup>2</sup>Baskent University Faculty of Medicine, Adana Dr Turgut Noyan Research and Treatment Center, Department of Radiation Oncology, Adana, Turkey, <sup>3</sup>Hacettepe University Faculty of Medicine, Department of Radiation Oncology, Ankara, Turkey, <sup>4</sup>Acibadem University Medical School, Istanbul, Turkey, <sup>5</sup>Acibadem Maslak Hospital, Istanbul, Turkey, <sup>6</sup>Koc University, School of Medicine, Department of Radiation Oncology, Istanbul, Turkey, <sup>7</sup>Baskent University Medical School, Adana, Turkey, <sup>8</sup>Hacettepe University Medical School, Ankara, Turkey, <sup>9</sup>Baskent University Medical School, Ankara, Turkey, <sup>10</sup>Hacettepe University, School of Medicine, Department of Radiation Oncology, Ankara, Turkey

**Purpose/Objective(s):** To validate the ESMO-ESGO-ESTRO consensus risk grouping in endometrial cancer (EC) patients treated with external beam radiotherapy (EBRT) and/or vaginal brachytherapy (VBT) ± chemotherapy (CT) after comprehensive surgical staging.

**Materials/Methods:** 683 patients treated in four institutions were retrospectively evaluated. Patients were classified into 4 groups: low-risk (LR), intermediate risk (IR), high-intermediate risk (HIR), and high-risk (HR). VBT was performed in patients with deep myometrial invasion (MI) or grade 3 histology. EBRT±VBT was performed when cervical stromal invasion, positive/close surgical margin, or extra-uterine extension was found. Adjuvant CT was applied in patients with stage III disease and non-endometrioid histology (NEH).

**Results:** Median follow-up was 56 months. 5-year overall survival (OS) and relapse-free survival (RFS) rate was 86% and 83%, respectively. A significant difference in OS was found between LR and HR groups ( $p=0.03$ ) and a trend between LR and HIR groups ( $p=0.054$ ). RFS rates were significantly different between LR and HIR ( $p=0.04$ ), LR and HR ( $p=0.007$ ), and IR and HR groups ( $p=0.01$ ). No statistically significant difference was found in OS and RFS between HIR and HR groups. Median time to recurrence was 53 months. Loco-regional recurrence (LRR) and distant metastasis (DM) developed in 41 (6%) and 68 (10%) patients, respectively. Twenty (3%) patients had both LRR and DM. LRR and DM were significantly higher in the HIR and HR groups compared to other groups ( $p=0.009$  and  $p=0.003$ , respectively). Two- and 5-year OS and RFS rate in the HR subgroups is listed in Table 1. OS rate was significantly higher in stage IB-grade 3 and stage II compared to stage III and NEH. There was no statistically significant difference between stage IB-grade 3 and stage II ( $p=0.9$ ), and between stage III and NEH ( $p=0.4$ ). RFS rate was significantly higher in stage IB-grade 3 and stage II compared to stage III and NEH. There was no significant difference between stage IB-grade 3 and stage II ( $p=0.5$ ), and stage III and NEH ( $p=0.8$ ).

**Conclusion:** The current risk grouping does not clearly discriminate the HIR and IR groups. Putting the stage IB-grade 3 and stage II with stage III

and NEH in the same prognostic group may be misleading. In patients with comprehensive surgical staging, a further risk grouping is needed to distinguish the real HR group.

Abstract 2805; Table 1

Characteristic	2y OS (%)	5y OS (%)	2y RFS (%)	5y RFS (%)
IB-G3	98	91	97	88
II	96	89	89	83
III	93	75	89	70
NEH	86	76	82	72

**Author Disclosure:** M. Gultekin: None. O. Guler: None. S. Yuce Sari: None. B. Akkus Yildirim: None. T.Z. Mustafayev: None. B. Atalar: None. Y. Bolukbasi: None. H. Onal: None. H. Celik: None. K. Yuce: None. A. Ayhan: None. F. Yildiz: None.

## 2806

### Preoperative Evaluation Of Serum CA-125 Levels Maybe A More Significantly Prognostic Factor In Low To Intermediate-risk Endometrial Carcinoma: A Multi-institutional Study



X. Hou,<sup>1</sup> M. Shi,<sup>2</sup> L. Wei,<sup>3</sup> L. Zou,<sup>4</sup> T. Wang,<sup>5</sup> Z. Liu,<sup>6</sup> J. He,<sup>7</sup> X. Sun,<sup>8</sup> W. Zhong,<sup>9</sup> F. Zhao,<sup>10</sup> X. Li,<sup>11</sup> S. Li,<sup>12</sup> H. Zhu,<sup>13</sup> Z. Ma,<sup>14</sup> M. Jin,<sup>15</sup> K. Hu,<sup>16</sup> and F. Zhang<sup>17</sup>; <sup>1</sup>Department of Radiation Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, <sup>2</sup>Department of Radiation Oncology, Xijing Hospital, Air Force Medical University, Xi'an, China, <sup>3</sup>Department of Radiation Oncology, Xijing Hospital, Air Force Medical University of PLA, Xi'an, China, <sup>4</sup>Department of Radiation Oncology, The Second Affiliated Hospital of DaLian Medical University, DaLian, China, <sup>5</sup>Department of Radiation Oncology, The second hospital of Jilin university, Jilin, China, <sup>6</sup>Department of Radiation Oncology, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China, <sup>7</sup>Department of Radiation Oncology, General Hospital of Ningxia Medical University, Yinchuan, Ningxia 750004, China, Yinchuan, China, <sup>8</sup>Department of Radiation Oncology, The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China, <sup>9</sup>Gynaecological Oncology Radiotherapy, Affiliated Tumor Hospital, Xinjiang Medical University, Xinjiang, China, <sup>10</sup>Department of Radiation Oncology, Gansu Provincial Cancer Hospital, Gansu, China, <sup>11</sup>Department of Radiation Oncology, Peking University First Hospital, Beijing, China, <sup>12</sup>Department of Radiation Oncology, Lanzhou General Hospital of People's Liberation Army, Lan Zhou, China, <sup>13</sup>Department of Radiation Oncology, Xiangya Hospital Central South University, Changsha, China, <sup>14</sup>Department of Radiation Oncology, Affiliated Hospital of Chifeng University, Inner Mongolia, China, <sup>15</sup>Department of Radiation Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, <sup>16</sup>Department of Radiation Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, <sup>17</sup>Department of Radiotherapy, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China

**Purpose/Objective(s):** To evaluate the prognostic role of preoperative serum CA-125 levels in different ESMO-ESGO-ESTRO risk classification in early-stage endometrial carcinoma (EC) from long-term data of a multi-institutional analysis.

**Materials/Methods:** The material for the current study was derived from a total of 1108 patients with early-stage EC from a multi-institutional analysis in China between 2000 and 2016. The eligibility criteria included the primary hysterectomy/bilateral salpingo-oophorectomy and adjuvant radiotherapy, stage I and II disease (FIGO 2009 staging) with complete clinicopathologic and follow-up information, serum CA-125 levels were evaluated preoperatively. Risk classification according to ESMO-ESGO-ESTRO Consensus. Time to any event was measured from the day RT started. Overall survival (OS), cancer-specific survival (CSS), disease free